<DOC>
	<DOC>NCT00744276</DOC>
	<brief_summary>The purpose of this study is to determine the safety of three doses of topically applied danazol compared to placebo in subjects with pain associated with fibrocystic breast disease and to determine the appropriate clinical dose for future studies.</brief_summary>
	<brief_title>A Study of Topical Danazol for the Treatment of Pain Associated With Fibrocystic Breast Disease</brief_title>
	<detailed_description />
	<mesh_term>Breast Diseases</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Fibrocystic Breast Disease</mesh_term>
	<mesh_term>Danazol</mesh_term>
	<criteria>Menstruating females at least 18 years of age Has moderate to severe breast pain associated with cyclical fibrocystic breast disease Is in good general health Pregnant within the past 6 months or lactating History of malignancy or currently being treated for cancer of the breast or genital organs Has taken within the past 3 months or is currently taking hormonal contraception Has any condition for which an androgen or steroid is contraindicated Has had breast implants or breast reduction surgery</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>fibrocystic breast disease</keyword>
	<keyword>fibrocystic disease of breast</keyword>
	<keyword>breast pain</keyword>
	<keyword>mastalgia</keyword>
	<keyword>cyclic mastalgia</keyword>
	<keyword>cystic breast disease</keyword>
</DOC>